<?xml version="1.0" encoding="UTF-8"?>
<p>If we consider that a whole virus inactivated vaccine with a potent QS21 saponin adjuvant is the ideal formulation for an anti-COVID-19 urgent first vaccine, the Sinovac vaccine is not only the closest formulation to the ideal, only differing in the adjuvant, but also the one that can be developed the fastest. The potential use of alum, MF59, AS03, AS04, or AS01, which contain QS21 saponin has been discussed (
 <xref rid="B53" ref-type="bibr">53</xref>, 
 <xref rid="B62" ref-type="bibr">62</xref>). It was concluded that, the immunopathology of SARS vaccines was a consequence to a Th2 type of response to the antigen and it was avoided in vaccines that drive the response to a Th1 immunity, with or without adjuvants (
 <xref rid="B53" ref-type="bibr">53</xref>).
</p>
